Thermo Fisher Scientific 8-K

PositiveEarningsGuidance deferred to the call

Growth strategy and PPI execution supported 6% Y/Y organic revenue growth; microbiology business divestiture completed

Filed 2026-10-21 06:03 ET

Summary

Q3 2026 results. Revenue grew 9%, including 6% organic growth; Thermo Fisher said performance reflected its growth strategy and PPI execution. The company completed its previously announced microbiology business divestiture and will update FY2026 guidance on its 10/21 earnings call.

Key Figures

Metric Q3 2026 9M 2026
Revenue $12.1B, +9% Y/Y $35.1B, +9% Y/Y
GAAP operating income $2.26B, +17% Y/Y $6.21B, +13% Y/Y
Non-GAAP adjusted operating income $2.97B, +15% Y/Y $8.10B, +12% Y/Y
GAAP operating margin 18.6%, vs 17.4% 17.7%, vs 17.0%
Non-GAAP adjusted operating margin 24.5%, vs 23.3% 23.1%, vs 22.4%
Net income attributable to Thermo Fisher Scientific Inc. $1.72B, +7% Y/Y $5.11B, +8% Y/Y
GAAP diluted EPS $4.64, +9% Y/Y $13.75, +10% Y/Y
Non-GAAP adjusted EPS $6.68, +15% Y/Y $18.15, +11% Y/Y
GAAP operating cash flow $2.55B, +14% Y/Y $5.87B, +35% Y/Y
Non-GAAP free cash flow $2.12B, +15% Y/Y $4.62B, +39% Y/Y
  • Q3 reported revenue growth included 3 percentage points from acquisitions/divestitures and no currency impact; organic revenue growth was 6%.
  • 9M share repurchases were $4.0B vs $2.96B a year earlier; weighted-average diluted shares were 372M vs 378M.
  • At 9/26/2026, cash and cash equivalents were $5.46B, vs $9.85B at 12/31/2025; short-term obligations and current maturities plus long-term obligations totaled $41.4B, vs $39.4B.

Guidance

Guidance to be given on the earnings call.

Investor Takeaways

  • Watch the FY2026 guidance update on the 10/21 earnings call for the company’s outlook following Q3 revenue and EPS growth.

Was this summary useful?

The summary is written by an AI model reading the filing.

Model 005 · prompt v95 · 2026-10-21 14:36:34Z

Feedback